APLM (Apollomics) Change In Payables And Accrued Expense : $-0.57 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apollomics Change In Payables And Accrued Expense?

Apollomics's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was $-1.89 Mil. It means Apollomics's Accounts Payable & Accrued Expense declined by $1.89 Mil from Jun. 2024 to Dec. 2024 .

Apollomics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2024 was $-0.57 Mil. It means Apollomics's Accounts Payable & Accrued Expense declined by $0.57 Mil from Dec. 2023 to Dec. 2024 .

Apollomics Change In Payables And Accrued Expense Historical Data

The historical data trend for Apollomics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollomics Change In Payables And Accrued Expense Chart

Apollomics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Payables And Accrued Expense

4.00

3.10

2.84

-2.64

-0.57

Apollomics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial				2.20	-0.31	-2.33	1.32	-1.89

Apollomics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.57 Mil.

Apollomics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Apollomics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apollomics Inc (NAS:APLM) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

APLMW:USA

Address

989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404

Website

https://www.apollomicsinc.com

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.